Neoadjuvant Endocrine Therapy: Who Benefits Most?

Area of Science:

• Oncology
• Endocrinology
• Cancer Therapeutics

Background:

• Estrogen receptor-positive (ER+) tumors are a significant subset of breast cancer.
• Neoadjuvant endocrine therapy (NET) is used to treat ER+ breast cancer before surgery.
• Identifying endocrine sensitivity and resistance is crucial for effective treatment strategies.

Purpose of the Study:

• To evaluate the role of neoadjuvant endocrine therapy (NET) in managing ER+ tumors.
• To investigate NET's efficacy in downstaging tumors and identifying endocrine-resistant cases.
• To explore prognostic markers for patient stratification in response to NET.

Main Methods:

• Administration of neoadjuvant endocrine therapy (NET) to patients with ER+ tumors.
• Assessment of tumor response, including downstaging.
• Analysis of tumor characteristics to determine endocrine sensitivity and resistance.

Main Results:

• NET demonstrates effectiveness in reducing tumor size (downstaging) in ER+ patients.
• NET successfully identifies tumors that are sensitive to endocrine treatment.
• NET also highlights tumors exhibiting endocrine resistance, necessitating alternative strategies.

Conclusions:

• Neoadjuvant endocrine therapy is a valuable tool for ER+ tumor management.
• NET aids in identifying patients who may benefit from intensified treatment regimens.
• Further research into prognostic markers is needed to optimize patient stratification and treatment selection.